CO5630029A2 - Derivados de indol e indolina sustituidos - Google Patents

Derivados de indol e indolina sustituidos

Info

Publication number
CO5630029A2
CO5630029A2 CO05118919A CO05118919A CO5630029A2 CO 5630029 A2 CO5630029 A2 CO 5630029A2 CO 05118919 A CO05118919 A CO 05118919A CO 05118919 A CO05118919 A CO 05118919A CO 5630029 A2 CO5630029 A2 CO 5630029A2
Authority
CO
Colombia
Prior art keywords
ilo
cycloalkyl
alkyl
cycloalk
cyano
Prior art date
Application number
CO05118919A
Other languages
English (en)
Inventor
Nikolay Khanzhin
Mario Rottlander
William Patrick Watson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO5630029A2 publication Critical patent/CO5630029A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

1.- Un derivado de indol o indolina sustituido de fórmula general I en el cual la linea punteada representa un enlace opcional;R1 y R1AND#39 se seleccionan en forma independiente del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxi-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halo-alqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halo-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ciano-alqu(en/in)ilo C1-6, ciano-cicloalqu(en)ilo C3-8 y ciano-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; o R1 y R1´ junto con el átomo de carbono al cual están unidos forman un anillo saturado o insaturado de 3-8 miembros que contiene, en forma opcional, 1 o 2 heteroátomos;S es 0 o 1;U es O, NR11, S, SO2, SO2NR11, CO-O o CO-NR11; en los cuales R11 se selecciona del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; o R2 y R11 junto con el átomo de nitrógeno al cual están unidos forman un anillo saturado o insaturado de 4-8 miembros que contiene, en forma opcional, 1, 2 o 3 heteroátomos adicionales;R2 se selecciona del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, Ar, Ar-alqu(en/in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, Ar-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, acilo, hidroxialqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxicicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halógeno, haloalqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halocicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ciano, cianoalqu(en/in)ilo C1-6, ciano-cicloalqu(en)ilo C3-8, cianocicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, -NO2, NR10R10AND#39-alqu(en/in)ilo C1-6, NR10R10AND#39-cicloalqu(en)ilo C3-8 y NR10R10AND#39-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; en los cuales R10 y R10AND#39 se seleccionan en forma independiente del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxicicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ...
CO05118919A 2003-04-25 2005-11-23 Derivados de indol e indolina sustituidos CO5630029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46538703P 2003-04-25 2003-04-25
DKPA200300631 2003-04-25

Publications (1)

Publication Number Publication Date
CO5630029A2 true CO5630029A2 (es) 2006-04-28

Family

ID=33420358

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05118919A CO5630029A2 (es) 2003-04-25 2005-11-23 Derivados de indol e indolina sustituidos

Country Status (8)

Country Link
US (1) US20060264496A1 (es)
EP (1) EP1631546A1 (es)
JP (1) JP2006524641A (es)
AU (1) AU2004233941A1 (es)
CO (1) CO5630029A2 (es)
MX (1) MXPA05010174A (es)
NO (1) NO20055562L (es)
WO (1) WO2004096767A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL166313A0 (en) 2002-07-17 2006-01-15 Kyoto Pharma Ind Indoline derivatives and pharmaceutical compositions containing the same
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
WO2007022321A2 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
BRPI0707495A2 (pt) 2006-02-07 2011-05-03 H Lundbeck & Co As método para tratar ou reduzir os sintomas de esquizofrenia, uso de um abridor seletivo de canal de potássio kcnq, método de triagem de um composto, e, uso de um composto
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
PL2061465T3 (pl) 2006-08-23 2014-03-31 Valeant Pharmaceuticals Int Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
NZ577740A (en) * 2006-11-28 2012-06-29 Valeant Pharmaceuticals Int 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
WO2009015667A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
US8952034B2 (en) * 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012003392A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP2707361B1 (en) 2011-05-10 2017-08-23 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN112010808B (zh) * 2019-05-31 2021-11-30 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234942A (en) * 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
CZ294097B6 (cs) * 1995-02-02 2004-10-13 Smithklineábeechamáplc Indolový derivátŹ způsob jeho přípravy a farmaceutická kompozice s jeho obsahem
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
GB9919411D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
CA2438805A1 (en) * 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators of kcnq potassium channels
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체

Also Published As

Publication number Publication date
MXPA05010174A (es) 2005-11-08
AU2004233941A1 (en) 2004-11-11
JP2006524641A (ja) 2006-11-02
US20060264496A1 (en) 2006-11-23
NO20055562L (no) 2005-11-24
EP1631546A1 (en) 2006-03-08
WO2004096767A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
CO5630029A2 (es) Derivados de indol e indolina sustituidos
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR054081A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas
AR053186A1 (es) Derivados del 1- bencil indol carboxamida
BRPI0414817A (pt) derivados de ácido indol substituìdos e seu uso como inibidores de pai-l
AR058198A1 (es) Derivados de morfolina y composiciones farmaceuticas
CO5680403A2 (es) Antagonistas de mchr1r
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
AR108778A1 (es) Compuestos antibacterianos
AR063128A1 (es) Compuestos de aril - indol sustituido y sus usos metabolitosde tipo quinurenina / quinurenina como agentes terapeuticos
CO2021001217A2 (es) Inhibidores tipo indol y azaindol de enzimas pad
DOP2007000067A (es) Derivados de aminometilpiridina, su preparación y su aplicación en terapéutica
PE20060163A1 (es) Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas
CO6220956A2 (es) Derivados de pirazolona como inhibidores de pde4
ECSP078009A (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
AR048745A1 (es) Derivados de (indol-3-il)-heterociclicos
AR052332A1 (es) Derivados de benzdioxanpiperazina con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del snc
AR041080A1 (es) Compuestos de 5- croman- 5- il- etilamina substituidos y su uso para el tratamiento de glaucoma
AR075245A1 (es) Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen.
AR074915A1 (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos del aparato cardiovascular, glaucoma y otras patologias.
AR054120A1 (es) Compuestos de fenilpiridilpiperazina, procedimiento de preparacion, composiciones farmaceuticas que los contienen, y usos farmacologicos como antagonistas de receptores histaminergicos h3

Legal Events

Date Code Title Description
FC Application refused